These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8204898)

  • 1. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow.
    Gribben JG; Neuberg D; Barber M; Moore J; Pesek KW; Freedman AS; Nadler LM
    Blood; 1994 Jun; 83(12):3800-7. PubMed ID: 8204898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG; Neuberg D; Freedman AS; Gimmi CD; Pesek KW; Barber M; Saporito L; Woo SD; Coral F; Spector N
    Blood; 1993 Jun; 81(12):3449-57. PubMed ID: 8507880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
    Zwicky CS; Maddocks AB; Andersen N; Gribben JG
    Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
    Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
    Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
    Negrin RS; Pesando J
    J Clin Oncol; 1994 May; 12(5):1021-7. PubMed ID: 8164025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
    Gribben JG; Freedman As; Woo SD; Blake K; Shu RS; Freeman G; Longtine JA; Pinkus GS; Nadler LM
    Blood; 1991 Dec; 78(12):3275-80. PubMed ID: 1742487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
    Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
    Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.
    Gribben JG; Saporito L; Barber M; Blake KW; Edwards RM; Griffin JD; Freedman AS; Nadler LM
    Blood; 1992 Aug; 80(4):1083-9. PubMed ID: 1498325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG; Freedman AS; Neuberg D; Roy DC; Blake KW; Woo SD; Grossbard ML; Rabinowe SN; Coral F; Freeman GJ
    N Engl J Med; 1991 Nov; 325(22):1525-33. PubMed ID: 1944436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique.
    Sharp JG; Joshi SS; Armitage JO; Bierman P; Coccia PF; Harrington DS; Kessinger A; Crouse DA; Mann SL; Weisenburger DD
    Blood; 1992 Feb; 79(4):1074-80. PubMed ID: 1737092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients.
    Damiani D; Fanin R; Silvestri F; Grimaz S; Infanti L; Geromin A; Cerno M; Michieli M; Rinaldi C; Savignano C; Trani G; Fiacchini M; Baccarani M
    Blood; 1997 Jul; 90(1):36-42. PubMed ID: 9207435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients.
    Macintyre EA; Belanger C; Debert C; Canioni D; Turhan AG; Azagury M; Hermine O; Varet B; Flandrin G; Schmitt C
    Blood; 1995 Dec; 86(12):4691-8. PubMed ID: 8541563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
    Moos M; Schulz R; Martin S; Benner A; Haas R
    Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
    Widmer L; Pichert G; Jost LM; Stahel RA
    Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT.
    Martin H; Atta J; Bruecher J; Elsner S; Schardt C; Stadler M; von Melchner H; Hoelzer D
    Ann Hematol; 1994 Feb; 68(2):85-7. PubMed ID: 7511936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.